Biora Therapeutics Announces New Patent For Its NaviCap Targeted Oral Delivery Platform
Portfolio Pulse from Benzinga Newsdesk
Biora Therapeutics, Inc. (NASDAQ:BIOR) has received a patent issue notification from the U.S. Patent and Trademark Office for a method of treating gastrointestinal disorders using targeted delivery of JAK inhibitors with its NaviCap platform. The patent, which will be issued as US Patent No. 11,857,669, covers a range of JAK inhibitors for various indications. The NaviCap platform is part of a larger patent portfolio that includes 30 families, 86 granted patents, and 81 pending applications. Biora is preparing to initiate a phase 1 trial for its BT-600 program, which utilizes the targeted delivery technology.
December 19, 2023 | 1:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biora Therapeutics has been granted a new patent for its NaviCap targeted oral delivery platform, which is expected to strengthen its intellectual property portfolio and potentially enhance the company's value.
The issuance of a new patent typically strengthens a company's intellectual property position, which can be a positive signal to investors. The patent for the NaviCap platform, which is part of a larger portfolio, may increase investor confidence in Biora's innovative capabilities and its potential to bring new treatments to market, especially as the company is nearing the initiation of a phase 1 trial for its BT-600 program. This news is likely to be viewed positively in the short term, potentially leading to an increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100